Open study of quadrivalent VN-100 in healthy children

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 73 人开始时间: 2015年8月18日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 73

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

As a result of quadrivalent VN-100 in healthy children 3 to 13 years of age, the HI antibody titer was confirmed to have good immunogenicity in any strain. There were no serious AEs, and there were no serious safety issues.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 3age old 至 <= 12age old（—）
性别: All

入选标准

•Japanese healthy children

排除标准

•1)Subjects with history of seasonal influenza in the past 6 months
•2)Subjects with history of seasonal influenza vaccination in the past 6 months

研究者

发起方

DAIICHISANKYO Co.,Ltd.

相似试验

已完成

3 期

Open study of quadrivalent VN-100 in Japanese healthy volunteersProphylaxis of influenza infection

JPRN-jRCT2080222562DAIICHISANKYO Co.,Ltd.150

已完成

3 期

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)Pneumococcal Infections

NCT03731182Merck Sharp & Dohme LLC104

已完成

3 期

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of AgeSeasonal Influenza

NCT01209780Novartis Vaccines3,116

进行中（未招募）

3 期

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)Papillomavirus Infections

NCT04708041Merck Sharp & Dohme LLC700

已完成

3 期

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeInfections, StreptococcalStreptococcus Pneumoniae

NCT00814710GlaxoSmithKline360